Genzyme’s Lemtrada FDA Approval

Lemtrada

November 14, 2014, FDA approved Genzyme’s Lemtrada (alemtuzumab) for treating relapsing-remitting form of MS (multiple sclerosis).  Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS. Read the …

Continue reading